Skip to main content

Advertisement

SpringerLink
Log in

Roux-en-Y Esophagojejunostomy Ameliorates Renal Function Through Reduction of Renal Inflammatory and Fibrotic Markers in Diabetic Nephropathy

  • Original Contributions
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Background

Roux-en-Y bariatric surgery has been shown to have a remarkable and sustainable improvement in type 2 diabetes. Recent clinical studies have shown that bariatric surgery can improve or halt the development of diabetic microvascular complications such as nephropathy. However, the exact underlying mechanisms of surgical procedures are unknown. Here, we have investigated the effects of Roux-en-Y esophagojejunostomy (RYEJ) on renal function and inflammation and fibrosis biomarkers for renal injury in type 2 diabetic rats.

Methods

Sprague–Dawley rats with high fat diet and streptozotocin (STZ)-induced diabetes were randomly assigned into four groups: diabetic nephropathy (DN), DN treated with food restriction (DN-FR), DN treated with RYEJ surgery (DN-RYEJ), and DN-RYEJ sham (n = 6/group). Age-matched normal rats were assigned as control group. RYEJ and sham surgeries were performed. Hyperinsulinemic–euglycemic clamps with tracer infusion were completed to assess insulin sensitivity. Twenty-four hour urine albumin excretion rate (UAER) and glomerular filtration rate (GFR) were measured. The renal pathological injury was assessed by hematoxylin and eosin (HE) staining. Kidney messenger RNA (mRNA) and/or protein content/distribution of phospho-c-Jun NH2-terminal kinase (JNK), monocyte chemoattractant protein (MCP)-1, transforming growth factor (TGF)-β1, and mitogen-activated protein kinase phosphatase 5 (MKP5) were evaluated by real-time PCR and/or Western blotting/immunohistochemistry.

Results

Roux-en-Y esophagojejunostomy improved insulin sensitivity. RYEJ ameliorated renal function by improving UAER and GFR and attenuated glomerular hypertrophy after surgery. RYEJ also significantly downregulated the levels of JNK-mediated inflammatory response and upregulated the level of the anti-inflammatory mediator MKP5.

Conclusion

Roux-en-Y esophagojejunostomy alleviates insulin resistance. RYEJ surgery ameliorated renal function and attenuated glomerular hypertrophy in a DN rat model. The considerable nephroprotective function may be mainly attributed to the reduced inflammatory and fibrotic biomarkers after RYEJ. The improvements in renal function and inflammation are not wholly dependent on the magnitude of weight loss.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Postma MJ, de Zeeuw D. The economic benefits of preventing endstage renal disease in patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 2009;24:2975–83.

    Article  PubMed  Google Scholar 

  2. Collins AJ, Foley RN, Chavers B, et al. United states renal data system 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the united states. Am J Kidney Dis. 2012;59(1 Suppl 1):A7. e1–420.

    Article  PubMed  Google Scholar 

  3. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol. 2004;286(1):F8–15.

    Article  CAS  PubMed  Google Scholar 

  4. Leon CA, Raij L. Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy. Hypertension. 2005;23(11):1931–7.

    Article  CAS  Google Scholar 

  5. Caramori ML, Mauer M. Diabetes and nephropathy. Curr Opin Nephrol Hypertens. 2003;12(3):273–82.

    Article  CAS  PubMed  Google Scholar 

  6. Docherty NG, LeRoux CW, Jackson S. Bariatric surgery and microvascular complications of type 2 diabetes mellitus. Curr Atheroscler Rep. 2014;16:453.

    Article  PubMed  Google Scholar 

  7. Fenske WK, Dubb S, Bueter M, et al. Effect of bariatric surgery induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis. 2013;9(4):559–68.

    Article  PubMed  Google Scholar 

  8. Miras AD, Chuah LL, Lascaratos G, et al. Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. Diabetes Care. 2012;35:e81.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yang F, Chung AC, Ru Huang X, et al. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent smad pathways: the role of Smad3. Hypertension. 2009;54:877–84.

    Article  CAS  PubMed  Google Scholar 

  11. Murphy M, Docherty NG, Griffin B, et al. IHG-1 amplifies TGF-beta1 signaling and is increased in renal fibrosis. Am Soc Nephrol. 2008;19:1672–80.

    Article  CAS  Google Scholar 

  12. Moustakas A, Heldin CH. Dynamic control of TGF-beta signaling and its links to the cytoskeleton. FEBS Lett. 2008;582:2051–65.

    Article  CAS  PubMed  Google Scholar 

  13. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807–69.

    CAS  PubMed  Google Scholar 

  14. Cohen MP, Shea E, Chen S, et al. Glycated albumin increases oxidative stress, activates NF-kB and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-B1 production in macrophage RAW cells. J Lab Clin Med. 2003;141:242–9.

    Article  CAS  PubMed  Google Scholar 

  15. Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stretch-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599–622.

    Article  CAS  PubMed  Google Scholar 

  16. Theodosiou A, Smith A, Gillieron C, et al. MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene. 1999;18:6981–8.

    Article  CAS  PubMed  Google Scholar 

  17. Zhang Y, Blattman JN, Kennedy NJ, et al. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature. 2004;430:793–7.

    Article  CAS  PubMed  Google Scholar 

  18. Ma FY et al. The role of stress-activated protein kinase signaling in renal pathophysiology. Braz J Med Biol Res. 2009;42(1):29–37.

    Article  CAS  PubMed  Google Scholar 

  19. Hofso D, Nordstrand N, Johnson LK, et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2010;163:735–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Navaneethan SD, Kelly KR, Sabbagh F, et al. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg. 2010;20:308–15.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Amor A, Jimenez A, Moize V, et al. Weight loss independently predicts urinary albumin excretion normalization in morbidly obese type 2 diabetic patients undergoing bariatric surgery. Surg Endosc. 2013;27:2046–51.

    Article  PubMed  Google Scholar 

  22. Agrawal V, Khan I, Rai B, et al. The effect of weight loss after bariatric surgery on albuminuria. Clin Nephrol. 2008;70:194–202.

    Article  CAS  PubMed  Google Scholar 

  23. He B, Yu C, Runyu D, et al. Roux-en-Y esophagojejunostomy reduces serum and aortic inflammatory biomarkers in type 2 diabetic rats. Obes Surg. 2014;24:916–26.

    Article  PubMed  Google Scholar 

  24. Srinivasan K, Viswanad B, Asrat L, et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52(4):313–20.

    Article  CAS  PubMed  Google Scholar 

  25. Bing H, Sheng Z, Zhang Wei L, et al. Salicylate prevents hepatic oxidative stress activation caused by short-term elevation of free fatty acids in vivo. Diabetes Res Clin Pract. 2010;89(2):150–6.

    Article  Google Scholar 

  26. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.

    Article  CAS  PubMed  Google Scholar 

  27. Dunn JP, Abumrad NN, Breitman I, et al. Hepatic and peripheral insulin sensitivity and diabetes remission at 1 month after Roux-en-Y gastric bypass surgery in patients randomized to omentectomy. Diabetes Care. 2012;35(1):137–42.

    Article  CAS  PubMed  Google Scholar 

  28. Mima A, Matsubara T, Arai H, et al. Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy. Lab Investig. 2006;86:927–39.

    Article  CAS  PubMed  Google Scholar 

  29. Flatt PR, Day C, Bailey CJ. Review: bariatric surgery: to treat diabesity. Br J Diab Vasc Dis. 2009;9(3):103–7.

    Article  Google Scholar 

  30. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427–36.

    Article  PubMed  Google Scholar 

  31. Lanzarini E, Csendes A, Lembach H, et al. Evolution of type 2diabetes mellitus in non morbid obese gastrectomized patients with Roux en-Y reconstruction: retrospective study. World J Surg. 2010;34:2098–102.

    Article  PubMed  Google Scholar 

  32. Lee W. Sang Hoon Ahn, Jue Hee Lee, et al. Comparative study of diabetes mellitus resolution according to reconstruction type after gastrectomy in gastric cancer patients with diabetes mellitus. Obes Surg. 2012;22:1238–43.

    Article  PubMed  Google Scholar 

  33. Wang KC, Huang KH, Lan YT, et al. Outcome after curative surgery for gastric cancer patients with type 2 diabetes. World J Surg. 2013.

  34. Navaneethan SD, Yehnert H, Moustarah F, et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1565–74.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Meijer RI, van Wagensveld BA, Siegert CE, et al. Bariatric surgery as a novel treatment for type 2 diabetes mellitus: a systematic review. Arch Surg. 2011;146:744–50.

    Article  PubMed  Google Scholar 

  36. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2008. Obes Surg. 2009;19:1605–11.

    Article  PubMed  Google Scholar 

  37. Rao SR. Inflammatory markers and bariatric surgery: a meta analysis. Inflamm Res. 2012;61:789–807.

    Article  CAS  PubMed  Google Scholar 

  38. He B, Piao D, Yu C, et al. Amelioration in hepatic insulin sensitivity by reduced hepatic lipid accumulation at short-term after Roux-en-Y gastric bypass surgery in type 2 diabetic rats. Obes Surg. 2013;23(12):2033–41.

    Article  PubMed  Google Scholar 

  39. Kraynak AR, Storer RD, Jensen RD, et al. Extentand persistence of streptozotocin induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays. Toxicol Appl Pharmacol. 1995;135:279–86.

    Article  CAS  PubMed  Google Scholar 

  40. Fowler S, Kon V, Ma L, et al. Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery. Pediatr Nephrol. 2009;24(4):851–5.

    Article  PubMed  Google Scholar 

  41. Agnani S, Vachharajani VT, Gupta R, et al. Does treating obesity stabilize chronic kidney disease? BMC Nephrol. 2005;6:7.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Navaneethan SD, Yehnert H. Bariatric surgery and progression of chronic kidney disease. Surg Obes Relat Dis. 2009;5(6):662–5.

    Article  PubMed  Google Scholar 

  43. Navarro-Diaz M, Serra A, Romero R, et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow up. JASN. 2006;17(12 Suppl 3):S213–7.

    Article  PubMed  Google Scholar 

  44. Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. JASN. 2003;14(6):1480–6.

    Article  PubMed  Google Scholar 

  45. Alexander JW, Goodman HR, Hawver LR, et al. Improvement and stabilization of chronic kidney disease after gastric bypass. Surg Obes Relat Dis. 2009;5(2):237–41.

    Article  PubMed  Google Scholar 

  46. Afshinnia F, Wilt TJ, Duval S, et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant. 2010;25(4):1173–83.

    Article  PubMed  Google Scholar 

  47. Izzedine H, Coupaye M, Reach I, et al. Gastric bypass and resolution of proteinuria in an obese diabetic patient. Diabet Med. 2005;22(12):1761–2.

    Article  CAS  PubMed  Google Scholar 

  48. Perez G, Devaud N, Escalona A, et al. Resolution of early stage diabetic nephropathy in an obese diabetic patient after gastric bypass. Obes Surg. 2006;16(10):1388–91.

    Article  PubMed  Google Scholar 

  49. Zhiqing W, Jing W, Haili X, et al. Renal function is ameliorated in a diabetic nephropathy rat model through a duodenal-jejunal bypass. Diabetes Res Clin Pract. 2014;103:26–34.

    Article  PubMed  Google Scholar 

  50. Hopkins PN. Molecular biology of atherosclerosis. Physiol Rev. 2013;93(3):1317–542.

    Article  CAS  PubMed  Google Scholar 

  51. Lee JY, Yu BP, Chung HY. Activation mechanisms of endothelial NF-kappaB, IKK, and MAP kinase by tertbutyl hydroperoxide. Free Radic Res. 2005;39(4):399–409.

    Article  CAS  PubMed  Google Scholar 

  52. Kim YW, West XZ, Byzova TV. Inflammation and oxidative stress in angiogenesis and vascular disease. Mol Med. 2013;91(3):323–8.

    Article  CAS  Google Scholar 

  53. Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell Signal. 2004;16:769–79.

    Article  CAS  PubMed  Google Scholar 

  54. Bueter M, Dubb SS, Gill A, et al. Renal cytokines improve early after bariatric surgery. Br J Surg. 2010;97:1838–44.

    Article  CAS  PubMed  Google Scholar 

  55. Monte SV, Caruana JA, Ghanim H, et al. Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery. 2012;151:587–93.

    Article  PubMed  Google Scholar 

  56. He B, Liu L, Yu C, et al. Roux-en-Y gastric bypass reduces lipid overaccumulation in liver by upregulating hepatic autophagy in obese diabetic rats. Obes Surg. 2015;25:109–18.

    Article  PubMed  Google Scholar 

  57. Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Diabetologia. 2009;52(11):2270–6.

    Article  CAS  PubMed  Google Scholar 

  58. Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab. 2009;35(6 Pt 2):518–23.

    Article  CAS  PubMed  Google Scholar 

  59. Luk AO, So WY, Ma RC, et al. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong diabetes registry. Diabetes Care. 2008;31(12):2357–61.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Rutkowski P, Klassen A, Sebekova K, et al. Renal disease in obesity: the need for greater attention. J Ren Nutr. 2006;16:216–23.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a Research Fund for the Doctoral Program of Higher Education of China (grant no. 20112104110014) and an Outstanding Scientific Fund of Shengjing Hospital (grant no. 201101).

Author information

Authors and Affiliations

  1. Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China

    Cuifang Wang, Bing He, Dongxu Piao & Ping Han

  2. Chinese People’s Liberation Army 202 Hospital, Shenyang, China

    Cuifang Wang

Authors
  1. Cuifang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bing He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dongxu Piao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ping Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ping Han.

Ethics declarations

Conflict of Interest

All contributing authors declare that they have no conflicts of interest.

Ethical Approval

My study is about animal experiment, and the following statement has been included: “All applicable national and international guidelines for the care and use of animals were followed.”

Informed Consent

This does not apply to my submission, the statement: “Does not apply” has been included.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, C., He, B., Piao, D. et al. Roux-en-Y Esophagojejunostomy Ameliorates Renal Function Through Reduction of Renal Inflammatory and Fibrotic Markers in Diabetic Nephropathy. OBES SURG 26, 1402–1413 (2016). https://doi.org/10.1007/s11695-015-1947-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-015-1947-5

Keywords

Search

Navigation